期刊
BRITISH JOURNAL OF PHARMACOLOGY
卷 180, 期 3, 页码 264-278出版社
WILEY
DOI: 10.1111/bph.15991
关键词
chaperones; cystathionine beta-synthase; enzyme therapy; gene therapy; homocystinuria; pegtibatinase; proteasome inhibitors
Homocystinuria, a common metabolic disorder, is characterized by increased homocysteine levels, leading to various clinical complications. Current treatment primarily involves dietary interventions, but alternative therapies such as enzyme and gene therapies have been explored.
Cystathionine beta-synthase (CBS)-deficient homocystinuria (HCU) is the most common inborn error of sulfur amino acid metabolism. The pyridoxine non-responsive form of the disease manifests itself by massively increasing plasma and tissue concentrations of homocysteine, a toxic intermediate of methionine metabolism that is thought to be the major cause of clinical complications including skeletal deformities, connective tissue defects, thromboembolism and cognitive impairment. The current standard of care involves significant dietary interventions that, despite being effective, often adversely affect quality of life of HCU patients, leading to poor adherence to therapy and inadequate biochemical control with clinical complications. In recent years, the unmet need for better therapeutic options has resulted in development of novel enzyme and gene therapies and exploration of pharmacological approaches to rescue CBS folding defects caused by missense pathogenic mutations. Here, we review scientific evidence and current state of affairs in development of recent approaches to treat HCU.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据